Back

The Drug-Induced Respiratory Disease Website and App

XV.x

XV - Pathology

Path: Acute/subacute bronchiolitis (see also IVc, IVi)

Last update 17/06/2026

See PMID 20441501. Some cases demonstrate associated ILD (PMID 18486892)

Causative drugs

12

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

Chemicals
I.a
I.b
I.d
I.j
I.af
II.a
II.b
III.a
III.b
IV.c
IV.n
IV.q
V.a
VIII.c
VIII.h
X.m
X.u
X.ac
XI.o
XII.m
XIV.a
XIV.b
XV.x
XVI.ab
XVII.p
Diacetyl (2,3-butanedione) flavoring agent
IV.c
IV.n
XV.x
XV.z
XV.cv
Disinfectants (humidifier disinfectants used in the home or occupational setting)
I.a
I.b
II.b
IV.v
XV.x
E-cigarette - E-vaporizers - ENDS - Vaping - Dabbing
I.a
I.b
I.c
I.d
I.e
I.f
I.j
I.m
I.n
I.u
I.v
I.aw
I.ax
II.b
II.t
III.a
III.c
III.m
IV.a
IV.d
IV.f
IV.k
IV.n
IV.p
IV.q
IV.t
IV.v
IV.ad
IV.al
V.a
V.f
VII.a
VII.e
VII.h
VIII.d
VIII.al
VIII.an
VIII.ap
VIII.at
VIII.aw
VIII.bb
VIII.bc
IX.h
IX.af
X.b
X.k
X.q
X.aq
XI.b
XI.n
XI.y
XI.as
XI.aw
XI.ax
XI.ay
XII.a
XII.l
XII.ag
XIV.a
XV.c
XV.d
XV.e
XV.f
XV.g
XV.p
XV.x
XV.y
XV.ab
XV.ba
XV.bi
XVI.a
XVI.b
XVI.d
XVI.g
XVI.k
XVI.v
XVI.af
XVI.ai
XVI.bl
XVII.a
XVII.c
XVII.h
XVII.ac
XVIII.x
XIX.a
XIX.b
XIX.c
XIX.d
XIX.f
XIX.i
XIX.n
E-cigarette's, e-vaporizer's secondhand vapor (Passive vaping)
I.b
I.m
IV.al
XV.e
XV.x
Immune checkpoint inhibitors (ICI) - ICI combinatorial Rx
I.a
I.b
I.c
I.d
I.e
I.f
I.g
I.u
I.v
I.w
I.y
I.aa
I.ad
I.aj
I.ax
II.b
II.d
III.m
IV.a
IV.c
IV.n
IV.y
IV.ab
IV.al
V.a
V.i
V.s
VI.a
VI.b
VII.a
VIII.t
IX.a
IX.d
IX.r
IX.ab
IX.ac
X.a
X.c
X.d
X.e
X.f
X.g
X.h
X.j
X.k
X.m
X.n
X.s
X.u
X.am
X.an
X.aw
X.ay
X.bi
XI.k
XI.u
XI.ac
XI.aq
XI.ar
XI.au
XII.a
XII.c
XII.d
XII.e
XII.g
XII.l
XII.n
XII.r
XII.s
XII.ai
XII.ax
XII.ba
XV.a
XV.b
XV.c
XV.d
XV.e
XV.f
XV.l
XV.v
XV.x
XV.ba
XV.ca
XV.co
XV.cp
XV.cw
XVI.k
XVI.v
XVI.w
XVI.bh
XVI.bm
XVI.bt
XVII.b
XVII.c
XVII.e
XVII.g
XVII.q
XVII.r
XIX.a
XIX.b
XIX.c
Marijuana (haschish), synthetic
I.a
XV.c
XV.x
XVI.u
XVI.v
XVI.ai
Nitrofurantoin
I.a
I.b
I.c
I.d
I.e
I.g
I.l
I.r
I.v
I.ax
II.a
II.b
II.j
III.a
IV.a
IV.ae
V.a
V.b
V.d
V.i
VI.d
VII.a
VIII.b
IX.i
X.a
X.d
X.e
X.f
X.s
XI.b
XI.c
XI.bg
XV.a
XV.b
XV.c
XV.e
XV.f
XV.h
XV.j
XV.k
XV.x
XV.ac
XV.af
XV.bi
XV.bl
XVI.b
XVI.f
XVI.l
XVI.bc
XVI.bp
Nivolumab
I.a
I.b
I.c
I.d
I.e
I.f
I.h
I.ad
I.aj
II.b
II.d
III.g
III.j
III.m
IV.a
IV.c
IV.j
IV.n
IV.y
IV.ab
IV.al
V.a
V.m
VI.b
VIII.t
VIII.ba
IX.a
IX.d
IX.h
IX.r
IX.y
IX.ab
X.a
X.d
X.f
X.g
X.j
X.k
X.m
X.n
X.s
X.u
X.ac
X.ay
XI.ar
XI.bn
XII.c
XII.d
XII.g
XII.n
XII.s
XII.ai
XII.ax
XV.c
XV.d
XV.g
XV.x
XV.bb
XV.cv
XVI.i
XVI.v
XVI.w
XVI.ab
XVI.af
XVI.ai
XVII.a
XVII.c
XVII.g
XVII.aj
XIX.a
XIX.b
XIX.c
XXVII.b
XXVII.e
Organic dust
I.a
I.b
I.g
I.an
II.b
XV.a
XV.h
XV.x
XVI.b
XVI.c
XVI.v
Pembrolizumab
I.a
I.b
I.c
I.d
I.f
I.m
I.o
I.y
I.ad
II.b
III.h
III.l
IV.a
IV.c
IV.d
IV.j
IV.k
IV.n
IV.t
IV.y
IV.ab
IV.ac
IV.ad
IV.al
V.m
VI.a
VI.b
VII.a
VII.e
VIII.q
VIII.t
IX.r
X.b
X.c
X.d
X.f
X.g
X.j
X.k
X.m
X.s
X.ah
X.an
X.aw
X.ax
X.ay
X.bi
XI.d
XI.k
XII.a
XII.c
XII.d
XII.r
XII.s
XV.a
XV.b
XV.c
XV.d
XV.e
XV.f
XV.x
XV.bb
XV.ca
XV.cw
XVI.b
XVI.e
XVI.k
XVI.v
XVI.z
XVI.ai
XVII.c
XVII.g
XVII.o
XIX.a
XIX.b
Vedolizumab
I.a
I.b
I.c
I.d
I.k
II.b
IV.c
VIII.aq
X.g
X.o
XV.b
XV.c
XV.e
XV.x
XV.cn
XVI.g
XVI.v
XVII.a
XVII.v
XXI.b